Skip to content

Research Performance

Infection Prevention & Control

Initiating and Delivering Clinical Research

The Government wishes to see a dramatic and sustained improvement in the performance of providers of NHS services in initiating and delivering clinical research. The aim is to increase the number of patients who have the opportunity to participate in research and to enhance the nation’s attractiveness as a host for research.

South East Coast NHS Ambulance Service NHS Foundation Trust produces quarterly reports detailing our performance against two performance benchmarks, set by the National Institute for Health Research (NIHR). These are designed to encourage quicker initiation of clinical trials and recruitment of the target number of participants within the timeframe agreed with the Sponsor.

SECAmb is required to submit information on the following two areas:

  • Initiating clinical research:

This benchmark requires SECAmb to recruit the first patient in to a clinical trial within 70 days of the date that the site was selected.

For Q3 2017-18:

REC Reference
Number

Integrated
Research
Number

Trial name

First
Patient
Recruited

Date of First Patient recruited

Date Site
Invited

Date Site
Selected

HRA Approval
Date

Date Site Confirmed
By Sponsor

Date Site
Confirmed

Date Site
Ready to
Start

Benchmark
met

Reason for this:

NHS 
Provider
Sponsor

Neither
Both
(or N/A
if the benchmark was met).

 

210175

MindSHINE 3: A definitive randomised controlled trial
Investigating
2 online well
Being interventions to Reduce NHS staff stress

Yes

24/05/2017

10/03/2017

13/03/2017

23/01/2017

02/05/2017

02/05/2017

22/05/2017

NO

Neither

Delivering commercial contract clinical research to time and target:

This benchmark requires SECAmb to report on whether the Trust is recruiting the target number of patients to clinical trials within the time frame agreed with the Sponsor. This applies to commercially sponsored trials only.

Currently SECAmb has no commercial clinical trials in place, so there is a

NIL return for Q3 2017-18.

Bookmark and Share